FDA compounding review of peptides

What FDA’s records say about the peptides it is reviewing for pharmacy compounding. An advisory recommendation or a pending review is not FDA approval.

For every peptide’s status in one table, including the October 30, 2026 HHS draft policy, see the status tracker.

Tracker sources checked through July 22, 2026.

8Tracked profiles
7July meeting profiles
1Separate review
16Cited source records

July 2026 FDA meeting

Profiles in the cited advisory process

Not FDA-approved↗

BPC-157↗

FDA staff recommended in May 2026 against adding BPC-157 to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists BPC-157 among six peptides that may be compounded under set conditions without federal enforcement action; it does not make BPC-157 an FDA-approved drug.↗↗↗↗

Inspect the profile and sources →
Not FDA-approved↗

KPV↗

FDA staff recommended in May 2026 against adding KPV to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists KPV acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make KPV an FDA-approved drug.↗↗↗↗

Inspect the profile and sources →
Not FDA-approved↗

TB-500↗↗

FDA staff recommended in May 2026 against adding TB-500 to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists TB-500 acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make TB-500 an FDA-approved drug.↗↗↗↗

Inspect the profile and sources →
Not FDA-approved↗

MOTS-c↗

FDA staff recommended in May 2026 against adding MOTS-c to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists MOTS-c acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make MOTS-c an FDA-approved drug.↗↗↗↗

Inspect the profile and sources →
Not FDA-approved↗

Semax↗

FDA staff recommended in May 2026 against adding Semax to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists Semax free base among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make Semax an FDA-approved drug.↗↗↗↗

Inspect the profile and sources →
Not FDA-approved↗

Epitalon↗

FDA staff recommended in May 2026 against adding epitalon to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists epitalon acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make epitalon an FDA-approved drug.↗↗↗↗

Inspect the profile and sources →

Separate FDA record

Route-specific GHK-Cu review

Not FDA-approved↗

GHK-Cu↗↗

Two randomized studies of copper-peptide skin and wound products report mixed results. FDA lists injected GHK-Cu among substances that may present significant safety risks. GHK-Cu is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗

Open the living status brief →